MX2019005874A - Administracion intratecal de virus recombinante adeno-asociado que codifica la proteina 2 que une metilo-cpg. - Google Patents
Administracion intratecal de virus recombinante adeno-asociado que codifica la proteina 2 que une metilo-cpg.Info
- Publication number
- MX2019005874A MX2019005874A MX2019005874A MX2019005874A MX2019005874A MX 2019005874 A MX2019005874 A MX 2019005874A MX 2019005874 A MX2019005874 A MX 2019005874A MX 2019005874 A MX2019005874 A MX 2019005874A MX 2019005874 A MX2019005874 A MX 2019005874A
- Authority
- MX
- Mexico
- Prior art keywords
- cpg
- adeno
- recombinant virus
- administration
- associated recombinant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Mycology (AREA)
- Marine Sciences & Fisheries (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423618P | 2016-11-17 | 2016-11-17 | |
| PCT/US2017/062371 WO2018094251A1 (en) | 2016-11-17 | 2017-11-17 | Intrathecal delivery of recombinant adeno-associated virus encoding methyl-cpg binding protein 2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019005874A true MX2019005874A (es) | 2020-02-07 |
Family
ID=62145776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019005874A MX2019005874A (es) | 2016-11-17 | 2017-11-17 | Administracion intratecal de virus recombinante adeno-asociado que codifica la proteina 2 que une metilo-cpg. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11583564B2 (enExample) |
| EP (1) | EP3541429A4 (enExample) |
| JP (3) | JP7106534B2 (enExample) |
| KR (1) | KR102641846B1 (enExample) |
| CN (2) | CN118490845A (enExample) |
| AU (3) | AU2017362491B2 (enExample) |
| BR (1) | BR112019009834B1 (enExample) |
| CA (1) | CA3044291A1 (enExample) |
| CL (1) | CL2019001354A1 (enExample) |
| IL (2) | IL322146A (enExample) |
| MA (1) | MA46863A (enExample) |
| MX (1) | MX2019005874A (enExample) |
| SA (1) | SA519401806B1 (enExample) |
| SG (1) | SG10202105090WA (enExample) |
| WO (1) | WO2018094251A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL322146A (en) * | 2016-11-17 | 2025-09-01 | Nationwide Childrens Hospital Inc | Intrathecal administration of adenovirus encoding methyl-CpG-binding protein 2 |
| EP4585229A3 (en) | 2017-11-08 | 2026-01-14 | Novartis AG | Means and method for preparing viral vectors and uses of same |
| JP7478675B2 (ja) | 2018-06-08 | 2024-05-07 | ノバルティス アーゲー | 薬物製品の効力を測定するための細胞ベースアッセイ |
| AR118005A1 (es) * | 2019-02-04 | 2021-09-08 | Res Institute At Nationwide ChildrenS Hospital | Administración del virus adenoasociado de polinucleótido de cln3 |
| JP7781057B2 (ja) * | 2019-10-18 | 2025-12-05 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | Ｉｒｆ２ｂｐｌ遺伝子の変異に関連する障害の治療のための材料および方法 |
| US20230211018A1 (en) * | 2019-11-22 | 2023-07-06 | Research Institute At Nationwide Children's Hospital | Materials and methods for treatment of disorders associated with the ighmbp2 gene |
| WO2022221424A1 (en) | 2021-04-13 | 2022-10-20 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus encoding methyl-cpg binding protein 2 for treating pitt hopkins syndrome via intrathecal delivery |
| CN121175427A (zh) * | 2023-05-15 | 2025-12-19 | 上海金珂博生物技术有限公司 | 一种Rett综合症的基因治疗 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| EP0733103B1 (en) | 1993-11-09 | 2004-03-03 | Targeted Genetics Corporation | Generation of high titers of recombinant aav vectors |
| DE69433922T2 (de) | 1993-11-09 | 2005-07-28 | Medical College Of Ohio, Toledo | Stabile zellinie, die in der lage ist, das replikationsgen des adenoassoziertenvirus zu exprimieren |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| RU2273645C9 (ru) | 1994-08-17 | 2006-11-27 | Дзе Рокефеллер Юниверсити | Полипептид ожирения (ов)(варианты), его аналог (варианты) и слитый белок (варианты), изолированная молекула нуклеиновой кислоты, молекула днк, рекомбинантный вектор клонирования, рекомбинантный вектор экспрессии, фармацевтическая композиция, моноклональное и поликлональное антитело |
| US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
| WO1996017947A1 (en) | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
| FR2737730B1 (fr) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
| JPH11511326A (ja) | 1995-08-30 | 1999-10-05 | ジエンザイム コーポレイション | アデノウィルスおよびａａｖの精製 |
| JPH11514853A (ja) | 1995-09-08 | 1999-12-21 | ジエンザイム コーポレイション | 遺伝子治療のための改良されたａａｖベクター |
| US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
| EP1696036B1 (en) | 1996-09-06 | 2010-04-21 | The Trustees of The University of Pennsylvania | Use of recombinant adeno-associated virus in the manufacture of a medicament for gene therapy via muscle cells |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| CA2995542A1 (en) | 1997-09-05 | 1999-03-11 | Genzyme Corporation | Methods for generating high titer helper-free preparations of recombinant aav vectors |
| US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| GB9916702D0 (en) * | 1999-07-16 | 1999-09-15 | Cantab Pharma Res | Virus vectors and preparations and their use |
| JP2004514407A (ja) | 2000-04-28 | 2004-05-20 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 異種キャプシド中にシュードタイピングされたａａｖ５キャプシドおよびａａｖ５ベクターを含む組換えａａｖベクター |
| EP1463805B1 (en) | 2001-12-17 | 2014-10-22 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor |
| US9233131B2 (en) | 2003-06-30 | 2016-01-12 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| CA2554380C (en) * | 2004-02-17 | 2015-05-19 | The Hospital For Sick Children | Mecp2e1 gene |
| EP3146982B1 (en) * | 2006-10-03 | 2019-08-21 | Genzyme Corporation | Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders |
| ES2579231T3 (es) | 2008-01-15 | 2016-08-08 | Abbvie Inc | Vectores de expresión de mamíferos mejorados y usos de los mismos |
| US20090246768A1 (en) * | 2008-02-15 | 2009-10-01 | Sawalha Amr H | Predicting and Diagnosing Patients With Autoimmune Disease |
| US9415121B2 (en) | 2008-12-19 | 2016-08-16 | Nationwide Children's Hospital | Delivery of MECP2 polynucleotide using recombinant AAV9 |
| US11219696B2 (en) | 2008-12-19 | 2022-01-11 | Nationwide Children's Hospital | Delivery of polynucleotides using recombinant AAV9 |
| DE102012007232B4 (de) | 2012-04-07 | 2014-03-13 | Susanne Weller | Verfahren zur Herstellung von rotierenden elektrischen Maschinen |
| JP2015092462A (ja) | 2013-09-30 | 2015-05-14 | Tdk株式会社 | 正極及びそれを用いたリチウムイオン二次電池 |
| WO2015141521A1 (ja) | 2014-03-21 | 2015-09-24 | 株式会社日立国際電気 | 基板処理装置、半導体装置の製造方法及び記録媒体 |
| JP6197169B2 (ja) | 2014-09-29 | 2017-09-20 | 東芝メモリ株式会社 | 半導体装置の製造方法 |
| JP6754361B2 (ja) * | 2014-12-16 | 2020-09-09 | ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ | 若年型バッテン病のための遺伝子療法 |
| IL322146A (en) * | 2016-11-17 | 2025-09-01 | Nationwide Childrens Hospital Inc | Intrathecal administration of adenovirus encoding methyl-CpG-binding protein 2 |
| EP3635122A4 (en) * | 2017-06-06 | 2021-03-31 | University of Massachusetts | SELF-REGULATING AAV VECTORS FOR THE SAFE EXPRESSION OF MECP2 IN RETT SYNDROME |
-
2017
- 2017-11-17 IL IL322146A patent/IL322146A/en unknown
- 2017-11-17 SG SG10202105090WA patent/SG10202105090WA/en unknown
- 2017-11-17 BR BR112019009834-8A patent/BR112019009834B1/pt active IP Right Grant
- 2017-11-17 IL IL266678A patent/IL266678B2/en unknown
- 2017-11-17 US US16/461,837 patent/US11583564B2/en active Active
- 2017-11-17 MX MX2019005874A patent/MX2019005874A/es unknown
- 2017-11-17 CA CA3044291A patent/CA3044291A1/en active Pending
- 2017-11-17 MA MA046863A patent/MA46863A/fr unknown
- 2017-11-17 CN CN202410270436.6A patent/CN118490845A/zh active Pending
- 2017-11-17 KR KR1020197017104A patent/KR102641846B1/ko active Active
- 2017-11-17 JP JP2019527321A patent/JP7106534B2/ja active Active
- 2017-11-17 EP EP17872045.4A patent/EP3541429A4/en active Pending
- 2017-11-17 WO PCT/US2017/062371 patent/WO2018094251A1/en not_active Ceased
- 2017-11-17 AU AU2017362491A patent/AU2017362491B2/en active Active
- 2017-11-17 CN CN201780072105.XA patent/CN110325219B/zh active Active
-
2019
- 2019-05-17 SA SA519401806A patent/SA519401806B1/ar unknown
- 2019-05-17 CL CL2019001354A patent/CL2019001354A1/es unknown
-
2022
- 2022-07-13 JP JP2022112657A patent/JP2022137210A/ja active Pending
-
2023
- 2023-01-02 US US18/149,151 patent/US12357663B2/en active Active
- 2023-04-28 AU AU2023202598A patent/AU2023202598B2/en active Active
-
2024
- 2024-01-24 JP JP2024008380A patent/JP7862454B2/ja active Active
-
2025
- 2025-06-20 US US19/244,103 patent/US20250312400A1/en active Pending
-
2026
- 2026-01-13 AU AU2026200191A patent/AU2026200191A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001354A1 (es) | Administración intratecal de virus recombinante adeno–asociado que codifica la proteína 2 que une metilo–cpg. | |
| CL2020003257A1 (es) | Compuestos antagonistas de pcsk9. | |
| MX2019015516A (es) | Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer. | |
| CL2018003754A1 (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo. | |
| CO2018013738A2 (es) | Novedosos virus vaccinia modificados genéticamente | |
| BR112018013995A2 (pt) | terapia de combinação de vírus oncolítico e inibidor de ponto de verificação | |
| SV2018005778A (es) | Derivados aromaticos de sulfonamida | |
| CY1125582T1 (el) | Συνθεσεις και μεθοδοι για εκλυση μακρας διαρκειας των ανταγωνιστων της εκλυτικης ορμονης των γοναδοτροπινων (gnrh). | |
| MX2016014187A (es) | Adenovirus que comprende una fraccion de union a albumina. | |
| CO2020015923A2 (es) | Antagonista de gremlin-1 para la prevención y tratamiento del cáncer | |
| MX2017001512A (es) | Compuestos activos hacia bromodominios. | |
| CL2019003430A1 (es) | Tratamiento conjunto antineoplásico. | |
| HUE058044T2 (hu) | Fenilpirrolidinon-formil peptid 2 receptor agonisták | |
| AR108468A1 (es) | POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS | |
| MX392945B (es) | Compuestos para la prevencion y el tratamiento de enfermedades y el uso de los mismos. | |
| CO2018014010A2 (es) | Anticuerpos a la alfa-sinucleína y usos de los mismos | |
| UY37456A (es) | Inmunoglobulinas y sus usos | |
| MX2015016627A (es) | Vacuna para la malaria. | |
| MX2018005544A (es) | Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar cancer. | |
| DOP2017000236A (es) | Neutralización del virus chikungunya mediada por anticuerpos | |
| PH12021550289A1 (en) | Ox40-binding polypeptides and uses thereof | |
| PE20181088A1 (es) | Mecanismo de resistencia a inhibidores de bromodominio bet | |
| CL2016002389A1 (es) | Compuestos derivados de amidopiridina, agonista inverso del receptor cannabinoide tipo 2 composicion farmaceutica procedimiento de preparación y uso de los compuestos en el tratamiento o profilaxis del dolor neuropatico, asma, osteoporosis, inflamacion, entre otros. | |
| BR112017023855A2 (pt) | o uso de estimulantes de sgc, ativadores de scg, em separado e combinações com inibidores de pde5 para o tratamento de úlceras digitais (du) concomitantes à esclerose múltipla (ssc) | |
| MX2019007107A (es) | Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o supercontigo sin ig anti-adm para su uso en intervencion y terapia de congestion en un paciente con necesidad del mismo. |